15 results on '"Delforge, Michel"'
Search Results
2. Recommendations on the management of multiple myeloma in 2020.
3. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.
4. Immunomodulators in newly diagnosed multiple myeloma: current and future concepts.
5. Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone.
6. Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.
7. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
8. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients.
9. Lack of clinical benefit of zoledronic acid in myelofibrosis: results of a prospective multi-center phase II trial.
10. Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations.
11. Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial.
12. Response evaluation and monitoring of multiple myeloma.
13. Patients with myelodysplastic syndrome and two clones with different interstitial deletions of the long arm of chromosome 5.
14. Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians.
15. Secondary central nervous system involvement in cyclin D1-negative mantle cell lymphoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.